Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status Prescription
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 0069-8141; 53869-2231; 68724-1020; 0069-8140; 72969-115; 53869-2230
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver injury12.01.02.003; 09.01.07.0220.001066%Not Available
Organising pneumonia22.01.02.0080.000533%Not Available
Hypertransaminasaemia09.01.02.0050.000533%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Skin sensitisation23.03.03.052; 10.02.01.0380.000533%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000764%Not Available
Candida infection11.03.03.0210.000799%
Myocardial necrosis marker increased13.04.01.0130.000799%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Liver function test increased13.03.01.0440.006127%Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.000139%Not Available
Bronchial carcinoma16.19.02.004; 22.08.01.0150.000417%Not Available
Carcinoembryonic antigen increased13.22.01.0090.002398%Not Available
Cellulitis orbital11.02.01.035; 06.04.11.0010.000533%Not Available
Full blood count decreased13.01.07.004--Not Available
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.001112%Not Available
Lung adenocarcinoma stage IV22.08.01.017; 16.19.01.0070.000208%Not Available
Lung carcinoma cell type unspecified stage IV22.08.01.019; 16.19.02.0060.000139%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000208%Not Available
Neuroblastoma17.20.03.002; 16.30.03.002; 05.01.04.0010.000208%Not Available
Non-small cell lung cancer stage IV22.08.01.022; 16.19.01.0100.000417%Not Available
Normal pressure hydrocephalus17.07.01.0020.000533%Not Available
Rectal perforation07.04.01.0040.000533%
Renal haematoma24.07.07.004; 20.01.02.018; 12.01.05.0060.000533%Not Available
Muscle abscess15.05.01.006; 11.01.17.0070.000799%Not Available
Subclavian vein thrombosis24.01.02.0130.000533%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000139%Not Available
Psoas abscess15.05.01.008; 11.01.17.0080.000799%Not Available
The 19th Page    First    Pre   19 20    Next   Last    Total 20 Pages